Login
Evidence Feed
About
Diagnostics
New
Top genes
FAQ
Contact us
^
Login
Contact us
to learn more about
our Premium Content: News alerts, weekly reports and conference planners
DRUG:
SLAMF7 FPBMC
i
Other names:
SLAMF7 FPBMC, SLAMF7 BATs/CS-1 BATs, anti-CD3 x anti-SLAMF7 bispecific antibody armed activated T cells
Contact us
to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Associations
News
Trials
Company:
University of Virginia
Drug class:
CS-1 inhibitor, CD3 inhibitor
Related drugs:
‹
elotuzumab (8)
RXDX-105 (5)
PVX-410 (0)
EGFR bi-armed autologous activated T cells (0)
MGD007 (0)
muromonab-CD3 (0)
VG712 (0)
ertumaxomab (0)
anti-CD3 x anti-CD20 bispecific antibody-armed activated T cells (0)
elotuzumab (8)
RXDX-105 (5)
PVX-410 (0)
EGFR bi-armed autologous activated T cells (0)
MGD007 (0)
muromonab-CD3 (0)
VG712 (0)
ertumaxomab (0)
anti-CD3 x anti-CD20 bispecific antibody-armed activated T cells (0)
›
Associations
News
Trials
Filter by
Latest
12ms
MM FPBMC: Phase I/II Study of SLAMF7 FPBMC/CS-1 FPBMC in Relapsed/Refractory Multiple Myeloma (clinicaltrials.gov)
P1/2, N=0, Withdrawn, University of Virginia
12 months ago
Trial completion date • Trial primary completion date
|
SLAMF7 (SLAM Family Member 7)
|
SLAMF7 FPBMC
1year
MM FPBMC: Phase I/II Study of SLAMF7 FPBMC/CS-1 FPBMC in Relapsed/Refractory Multiple Myeloma (clinicaltrials.gov)
P1/2, N=0, Withdrawn, University of Virginia | N=18 --> 0 | Recruiting --> Withdrawn
1 year ago
Enrollment change • Trial withdrawal
|
SLAMF7 (SLAM Family Member 7)
|
SLAMF7 FPBMC
over1year
MM FPBMC: Phase I/II Study of SLAMF7 FPBMC/CS-1 FPBMC in Relapsed/Refractory Multiple Myeloma (clinicaltrials.gov)
P1/2; Trial completion date: Jan 2030 --> May 2030 | Trial primary completion date: Jan 2027 --> May 2027
over 1 year ago
Trial completion date • Trial primary completion date
|
IFNG (Interferon, gamma) • SOX2 • SLAMF7 (SLAM Family Member 7)
|
clonoSEQ
|
SLAMF7 FPBMC
over1year
MM BATs: Phase I/II Study of SLAMF7 FPBMC/CS-1 FPBMC in Relapsed/Refractory Multiple Myeloma (clinicaltrials.gov)
P1/2; Not yet recruiting --> Recruiting | Phase classification: P1 --> P1/2 | Trial completion date: Jun 2028 --> Jan 2030 | Trial primary completion date: Jun 2027 --> Jan 2027
over 1 year ago
Trial completion date • Trial primary completion date • Phase classification • Enrollment open
|
IFNG (Interferon, gamma) • SOX2 • SLAMF7 (SLAM Family Member 7)
|
clonoSEQ
|
SLAMF7 FPBMC
over2years
MM BATs: Pilot Study of SLAMF7 BATs/CS-1 BATs in Relapsed/Refractory Multiple Myeloma (clinicaltrials.gov)
P1; Trial completion date: Jan 2027 --> Jun 2028 | Trial primary completion date: Jan 2026 --> Jun 2027
over 2 years ago
Trial completion date • Trial primary completion date
|
IFNG (Interferon, gamma) • SLAMF7 (SLAM Family Member 7)
|
clonoSEQ
|
SLAMF7 FPBMC
over3years
MM BATs: Pilot Study of SLAMF7 BATs/CS-1 BATs in Relapsed/Refractory Multiple Myeloma (clinicaltrials.gov)
P1; N=25; Not yet recruiting; Sponsor:University of Virginia
over 3 years ago
New P1 trial • Clinical
|
IFNG (Interferon, gamma) • SLAMF7 (SLAM Family Member 7)
|
clonoSEQ
|
SLAMF7 FPBMC
Share via
^
^
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login